Sarepta Halts Muscular Dystrophy Trial Because of Production IssuesAllbiopro2018-07-27T00:29:04+09:007월 27th, 2018|
Biogen Investors Underwhelmed by Alzheimer’s Study UpdateAllbiopro2018-07-27T00:28:38+09:007월 27th, 2018|
Novartis Taps Shyft Analytics To Drive Company’s Digital TransformationAllbiopro2018-07-27T00:28:12+09:007월 27th, 2018|
Thank you, Ocrevus: Roche ups guidance as MS drug steams past blockbuster markAllbiopro2018-07-27T00:27:45+09:007월 27th, 2018|
AstraZeneca’s new launches shine in Q2 as it inches toward turnaroundAllbiopro2018-07-27T00:27:19+09:007월 27th, 2018|
AstraZeneca’s selumetinib flops in thyroid cancer, adding to list of failuresAllbiopro2018-07-27T00:26:27+09:007월 27th, 2018|
GlaxoSmithKline’s Nucala hopes take a hit with FDA panel thumbs-down in COPDAllbiopro2018-07-27T00:26:01+09:007월 27th, 2018|
Quality blip halts Sarepta muscular dystrophy gene therapy trialAllbiopro2018-07-27T00:25:34+09:007월 27th, 2018|
Gilead’s top executives Milligan and Martin stepping downAllbiopro2018-07-27T00:25:08+09:007월 27th, 2018|
Biogen, Eisai’s anti-amyloid drug slows Alzheimer’s decline, but debate rages onAllbiopro2018-07-27T00:24:43+09:007월 27th, 2018|
Forget a consumer spinoff. GlaxoSmithKline is plotting a $525M cost-cutting drive insteadAllbiopro2018-07-27T00:24:18+09:007월 27th, 2018|
Takeda’s also-ran ALK drug Alunbrig aims to challenge Pfizer with new first-line dataAllbiopro2018-07-27T00:23:51+09:007월 27th, 2018|
A protein that promotes compatibility between chromosomes after fertilizationAllbiopro2018-07-27T00:22:32+09:007월 27th, 2018|
Litigation Expert Says Biosimilar Action Plan Provides “Tailwinds” to the IndustryAllbiopro2018-07-26T01:45:14+09:007월 26th, 2018|
